Effects of antibodies to sperm surface fertilization antigen-1 on human sperm-zona pellucida interaction

Ligands and Receptors Involved in the Sperm-Zona Pellucida Interactions in Mammals

Sperm-zona pellucida (ZP) interaction, involving the binding of sperm surface ligands to complementary carbohydrates of ZP, is the first direct gamete contact event crucial for subsequent gamete fusion and successful fertilization in mammals. It is a complex process mediated by the coordinated engagement of multiple ZP receptors forming high-molecular-weight (HMW) protein complexes at the acrosomal region of the sperm surface. The present article aims to review the current understanding of sperm-ZP binding in the four most studied mammalian models, i.e., murine, porcine, bovine, and human, and summarizes the candidate ZP receptors with established ZP affinity, including their origins and the mechanisms of ZP binding. Further, it compares and contrasts the ZP structure and carbohydrate composition in the aforementioned model organisms. The comprehensive understanding of sperm-ZP interaction mechanisms is critical for the diagnosis of infertility and thus becomes an integral part of assisted reproductive therapies/technologies.

Sperm-zona pellucida interaction: molecular mechanisms and the potential for contraceptive intervention

At the moment of insemination, millions of mammalian sperm cells are released into the female reproductive tract with the single goal of finding the oocyte. The spermatozoa subsequently ignore the thousands of cells they make contact with during their journey to the site of fertilization, until they reach the surface of the oocyte. At this point, they bind tenaciously to the acellular coat, known as the zona pellucida, which surrounds the oocyte and orchestrate a cascade of cellular interactions that culminate in fertilization. These exquisitely cell- and species- specific recognition events are among the most strategically important cellular interactions in biology. Understanding the cellular and molecular mechanisms that underpin them has implications for the etiology of human infertility and the development of novel targets for fertility regulation. Herein we describe our current understanding of the molecular basis of successful sperm-zona pellucida binding.

Sperm surface antigens and the prospects for contraceptive vaccine development

It has been estimated that 500 million couples world-wide have no access to contraception and that approximately 20% of births between 1995 and 2000 will be unwanted. Such statistics have important implications for the rate of world population growth and the possibility of maintaining a sustainable population. Although political change and the empowerment of women across the world will help address these issues, it will also be important to increase the availability of contraceptives; not only the modalities that are in current use, but also novel methods that will satisfy needs that are presently unfulfilled. One such alternative could be a vaccine targeting the human spermatozoon.

Immunisation of the male tammar wallaby (Macropus eugenii) with spermatozoa elicits epididymal antigen-specific antibody secretion and compromised fertilisation rate

Immunocontraception has been proposed as an effective and humane means of controlling overabundant kangaroo populations in Australia. We have examined the feasibility of using a sperm-based vaccine for this purpose using a model macropod species, the tammar wallaby (Macropus eugenii). This study has demonstrated immunocontraception in a marsupial species following immunisation of males with homologous spermatozoa. Serum anti-sperm IgG titres were associated with a significant reduction in fertilisation rates following mating with superovulated female wallabies. Antigen-specific IgG penetrated the reproductive tract at the rete testis and bound spermatozoa in vivo. IgG was detected bound to the acrosome and midpiece regions of both epididymal and ejaculated spermatozoa. The absence of adverse testicular pathology and sperm movement effects suggests that contraception may have been achieved by antibody-mediated blocking of sperm surface antigens essential for fertilisation. This study demonstrates that a contraceptive vaccine targeting sperm antigens has potential for fertility control in male macropods.

Contraceptive vaccines targeting sperm

Overpopulation is a global problem of significant magnitude, with grave implications for the future. Development of new contraceptives is necessary, as existing forms of birth control are unavailable, impractical and/or too expensive for many individuals due to sociological, financial or educational limitations. Immunocontraception and, in particular, the targeting of antibodies to sperm-specific antigens implicated in sperm-egg binding and fertilisation offers an attractive approach to control fertility. Sperm-specific antibodies may impair fertility by inhibiting sperm motility, by reducing penetration of the cervical mucus by sperm, or by interfering in sperm capacitation or the acrosome reaction; alternatively, antisperm antibodies may invoke the complement cascade, resulting in sperm lysis. The antibodies raised against sperm-specific antigens have proved to be extremely effective at reducing sperm-egg interactions in vitro; fertility trials in subhuman primates will eventually be needed to prove the effectiveness of the sperm antigens in terms of contraceptive efficacy before trials in humans can be justified. In addition, existing and emerging strategies (such as sperm proteomics, the determination of molecular and structural details of sperm proteins, and the modelling of protein-ligand interactions using X-ray and/or NMR structures to name a few) are expected to provide the experimental foundation for the design of small molecule inhibitors with antifertility effects. The technology underpinning vaccine development is constantly being developed and the introduction of DNA/RNA vaccines is certain to impact upon the field of immunocontraception.

Sperm specific proteins-potential candidate molecules for fertility control

The increase in population growth rate warrants the development of additional contraceptive methods that are widely acceptable, free from side effects and less expensive. Immunocontraception, and in particular the targeting of antibodies to gamete-specific antigens implicated in sperm egg binding and fertilization, offers an attractive approach to control fertility. The development of a contraceptive vaccine based on sperm antigen represents a promising approach to contraception. In mammals, fertilization is completed by the direct interaction of sperm and egg, a process mediated primarily by sperm surface proteins. Sperm have proteins that are unique, cell specific, immunogenic and accessible to antibodies. A few of the sperm specific proteins have been isolated and characterized. The antibodies raised against the sperm specific antigens have proved to be extremely effective at reducing sperm-egg interaction in vitro; fertility trials in sub-human primates would eventually prove the effectiveness of the sperm antigens in terms of contraceptive efficacy.

Molecular cloning and sequencing of cDNA encoding for human FA-1 antigen

The cDNA encoding for the human FA-1 sperm antigen was cloned and sequenced from the in-house constructed subtractive human testis cDNA expression library in lambda Ziplox using the FA-1 monoclonal antibody (mAb). The full--length sequence was obtained by using the 5' rapid amplification of 5'-cDNA end (5'-RACE) procedure. It is 1,576-bp long, and has an open reading frame (ORF) of 283 amino acids (aa) with the first ATG Met start codon at nucleotide (nt) 57 and the stop codon TAG at nt 906. It has two termination codons at the 5' end before the ATG start codon. The translated protein has a calculated molecular weight of 32.1 kDa and estimated isoelectric point (pI) of 11.59. It has one potential N-linked glycosylation site and one tyrosine phosphorylation site, besides several O-linked glycosylation and serine and threonine phosphorylation sites. Hydrophilicity analysis of the deduced aa sequence showed it to be a membrane-anchored protein. Extensive computer search in the database did not identify any known nt/aa sequence having homology with FA-1 cDNA or deduced aa, indicating it to be a novel gene. The Northern blot and reverse transcription-polymerase chain reaction (RT-PCR)-Southern blot analyses indicated the testis-specific expression of FA-1 antigen at the mRNA level. The ORF of the FA-1 was subcloned into pGEX- 1lambda T for expression. The expressed FA-1 recombinant protein had a molecular size of approximately 40 kDa, and was recognized by the FA-1 mAb, and not by the myeloma control Ig. The rabbit antibodies (Ab) raised against the recombinant (r) FA-1 antigen recognized the rFA-1 antigen as well as the native (n) FA-1 antigen. The rFA-1 Ab specifically recognized a protein band of approximately 50 kDa in human testis extract in the Western blot involving 11 types of human tissue extracts, indicating the testis-specific expression of FA-1 at the protein level. The Ab showed binding with live and methanol-fixed human sperm at the post-acrosomal, mid-piece, and tail regions. The Ab caused a significant (P < 0.001) and concentration-dependent inhibition of human sperm capacitation/acrosome reaction by blocking tyrosine phosphorylation of the FA-1 antigen. The sperm-specific human FA-1 recombinant antigen may find applications in immunocontraception, and diagnosis and treatment of immunoinfertility in humans.

Anti-SLIP1-reactive proteins exist on human spermatozoa and are involved in zona pellucida binding

Sulpholipid immobilizing protein 1 (SLIP1) is an evolutionarily conserved 68 kDa plasma membrane protein, present selectively in germ cells. We have previously shown that mouse sperm SLIP1 is involved in sperm-zona pellucida (ZP) binding. In this report, we extended our study to the human system. Immunoblotting demonstrated that anti-SLIP1-reactive proteins (mol. wt 68 and 48 kDa) could be extracted from human spermatozoa by an ATP-containing solution, a result that is consistent with observations in other species. Direct immunofluorescence, using Cy3-conjugated anti-SLIP1 IgG, revealed SLIP1 staining over the acrosomal region, with higher intensity at the posterior area. Using the human sperm-ZP binding assay, we demonstrated that pretreatment of human spermatozoa from three donors with anti-SLIP1 IgG revealed lower numbers of zona-bound spermatozoa, as compared to the corresponding control spermatozoa treated with normal rabbit serum IgG. This decrease in zona pellucida binding was not from an antibody-induced decline in sperm motility or an increase in the premature acrosome reaction. The results strongly suggest that anti-SLIP-reactive proteins on human spermatozoa play an important role in ZP binding.

Vaccine for contraception targeting sperm

Development of a vaccine(s) based on sperm antigens represents a promising approach to contraception. The utility of a sperm antigen in immunocontraception is contingent upon its tissue specificity, involvement in fertility and on raising high antibody titer, especially locally in the genital tract, that is capable of inducing reversible infertility. Several sperm antigens, such as lactate dehydrogenase C4, PH-20, sperm protein (SP)-10, fertilization antigen (FA)-1, FA-2, cleavage signal (CS)-1, NZ-1, and NZ-2 have been proposed as potential candidates for the vaccine development. Spermzona pellucida (ZP) binding is a pivotal tissue- and mostly species-specific event in the fertilization process, and the molecules involved in this site constitute the most exciting candidates for immuno-contraception. FA-1 is a sperm-specific glycoprotein having receptor activity for ZP recognition and binding. Complementary DNA encoding for FA-1 antigen has been cloned and sequenced. Active immunization of animals with recombinant FA-1 antigen causes a long-lasting reversible inhibition in fertility by raising a sperm-specific immune response. This antigen is also involved in human immunoinfertility. The exciting findings from the recent trial in immunoinfertile couples indicate that the FA-1 antigen may have clinical application in the treatment of male infertility. A vaccine having most appropriate tissue-specific and effective recombinant and/or synthetic epitopes of various sperm antigens, such as the FA-1 antigen, in a single formulation may provide a highly immunogenic and efficacious antisperm vaccine for contraception. The advances made during the last 5 years suggest that it may be a realistic proposition.

The potential use of sperm antigens as targets for immunocontraception; past, present and future

Immunocontraception, and in particular the targeting of antibodies to gamete-specific antigens implicated in sperm egg binding and fertilisation, offers an attractive approach to the growing global problem of overpopulation. Such an idea is not new; indeed several immunocontraception trials, using animal model systems, have been reported in recent years and a number are reviewed here. However, the results of these studies have been largely disappointing. We believe that two fundamental flaws attribute to the poor success of most of these preliminary immunocontraceptive trials. Firstly, loss of fertility has invariably been used as the assay. This presupposes that immuno-neutralisation of a single, gamete-specific antigen will be sufficient to cause a significant reduction in fertility; however, recent data suggests that such a premise may not be well-founded for a number of reasons. Secondly, and arguably the most important flaw, is the almost universal, but largely inappropriate, use of systemic immunisation as the sole route of antigen delivery. Whilst systemic immunisation regimes may lead to high serum IgG levels, these levels do not correlate with specific antibody levels in the reproductive tract or with contraceptive efficacy. Hence, an alternative antigen delivery approach is required which will induce an effective local immune response in the reproductive tract. Here we discuss the ways in which this might be achieved.

Fertilization antigen-1 removes antisperm autoantibodies from spermatozoa of infertile men and results in increased rates of acrosome reaction

OBJECTIVE

To determine if fertilization antigen (FA)-1 will remove autoantibodies from the surface of sperm cells of immunoinfertile men by immune adsorption and permit an increased acrosome reaction (AR).

DESIGN

Prospective analytic study.

SETTING

University medical center.

PATIENT(S)

Men from 18 infertile couples with autoantibodies present on their spermatozoa.

INTERVENTION(S)

Sperm samples after processing were examined for antibody binding and AR before and after adsorption with control medium or FA-1.

MAIN OUTCOME MEASURE(S)

Sperm-bound antibody was assessed by the immunobead assay (immunoglobulin [Ig] A and IgG) and the AR by induction with ionophore A23187.

RESULT(S)

Adsorption with FA-1 compared with control medium increased immunobead-free swimming sperm an average of 50% and 76% for IgA and IgG antisperm antibodies, respectively, with 78% and 100% of the 18 semen specimens increasing significantly. The AR rate increased an average of 10.3% compared with control medium and showed improvement in 78% of the sperm samples after FA-1 adsorption.

CONCLUSION(S)

The FA-1 sperm antigen appears to significantly free sperm cells coated with autoantibodies in the semen of most infertile men examined. Reducing sperm-bound antibodies that inhibited the AR allowed the sperm cells to undergo successful AR induction by calcium ionophore.

Fertilization antigen-1: cDNA cloning, testis-specific expression, and immunocontraceptive effects

cDNA encoding for a sperm antigen, designated fertilization antigen (FA-1), was cloned and sequenced from murine testis cDNA-lambdagt11 expression library using FA-1 mAb. Computer-generated translation analysis of 649-bp cDNA yielded an ORF of 164 amino acids with the first ATG Met start codon at nucleotide 81 and the stop codon TAA at nucleotide 577 and a polyadenylylation tail following the stop codon. The translated protein has a calculated molecular mass of 18.2 kDa and a potential N-linked glycosylation site at amino acids 158-160, besides at least two O-linked glycosylation sites. The hydropathy plot generated from the deduced amino acid sequence indicated it to be a membrane-anchored peptide. Extensive computer search in the GenBank, National Biomedical Research Foundation, and Swiss sequence banks did not identify any known nucleotide/amino acid sequence having homology with FA-1 cDNA or deduced amino acids, indicating it to be a novel protein. Northern blot analysis and reverse transcription-PCR indicated testis-specific expression of FA-1 antigen. The FA-1 cDNA was subcloned into pGEX-2T vector and expressed in glutathione S-transferase gene fusion system to obtain the recombinant protein. The recombinant protein specifically reacted with ZP3 of oocyte zona pellucida and its affinity-purified antibodies completely blocked sperm-zona pellucida interaction in mice. These findings suggest that the sperm-specific recombinant FA-1 antigen is an attractive candidate for the development of a contraceptive vaccine.

Protein tyrosine phosphorylation and signal transduction during capacitation-acrosome reaction and zona pellucida binding in human sperm

During capacitation and acrosome reaction of human sperm, 7-14 proteins are phosphorylated, and two of these proteins (95 and 51 kD) are phosphorylated at tyrosine resides. The sperm proteins that bind ZP3 in humans have molecular identities of 95, 63, 51 (FA-1 antigen), and 14-18 kD, respectively. Three of these molecules, 95-, 51-, and 14-18-kD proteins, undergo tyrosine phosphorylation, and 51 kD (FA-1 antigen) also undergoes autophosphorylation. Many of the sperm proteins that participate in ZP binding are also involved in capacitation/acrosome reaction. These findings indicate a vital role of protein tyrosine phosphorylation and tyrosine receptor kinases in sperm capacitation, acrosome reaction, and ZP binding. Since tyrosine phosphorylation is the primary, or even exclusive, indication of signal transduction, it would appear that a signal transduction pathway is involved in these processes. However, the exact mechanism requires further study.

Thymosin alpha-1 and FA-1 monoclonal antibody affect fertilizing capacity of human sperm by modulating protein phosphorylation pattern

The present investigation was conducted to investigate the modulation of phosphorylation pattern of human sperm membrane proteins during capacitation by thymosin alpha-1 (T alpha 1) (which enhanced sperm penetration index) and anti-FA-1 monoclonal antibody (anti-FA-1 mAb) (which completely blocked sperm penetration) using 32P metabolic labeling, in vitro kinase assay and Western immunoblot analysis. In 32P metabolic labeling experiments, T alpha 1 (0.25 and 0.5 microgram/100 microliters) enhanced phosphorylation of 7 proteins in four molecular regions namely one protein (190 kDa) in 200-kDa, two proteins (112 and 104 kDa) in 97-kDa, two proteins (48 and 42 kDa) in 43-kDa and two proteins (31 and 25 kDa) in 29-kDa molecular regions, respectively. Anti-FA-1 mAb (10 micrograms/100 microliters) resulted in a general decrease in the 32P labeling of these sperm proteins. In in vitro kinase assay using non-capacitated sperm extracts, T alpha 1 (0.5 microgram/100 microliters) enhanced autophosphorylation of 14 proteins in various molecular regions (122, 105, 95, 89, 73, 62, 48, 46, 40, 33, 30, 28, 25 and 22 kDa, respectively). The same concentration of T alpha 1 did not affect autophosphorylation of proteins in capacitated sperm extract. Anti-FA-1 mAb (10 micrograms/100 microliters) inhibited autophosphorylation of a subset of 8 proteins (122, 104, 95, 89, 73, 62, 48 and 46 kDa, respectively) in non-capacitated sperm membrane extracts, and 12 proteins (112, 104, 95, 89, 73, 62, 48, 46, 33, 30, 28 and 25 kDa, respectively) in capacitated sperm membrane extracts. In the Western immunoblot analysis, T alpha 1 resulted in a concentration-dependent increase in tyrosine phosphorylation of two proteins (95 and 51 kDa) during capacitation of human sperm, whereas anti-FA-1 mAb inhibited tyrosine phosphorylation of both proteins. These results indicate that T alpha 1 and anti-FA-1 mAb affect the fertilizing capacity of human sperm by modulating phosphorylation of proteins especially tyrosine phosphorylation of 95- and 51-kDa proteins during capacitation. These findings also suggest that there may be a signal transduction pathway(s) involved in phosphorylation of membrane proteins during capacitation and that an exogenous stimulus affecting a single membrane protein component can modulate phosphorylation of all the relevant proteins involved in capacitation/acrosome reaction of human sperm.

Fertilization antigen (FA-1) completely blocks human sperm binding to human zona pellucida: FA-1 antigen may be a sperm receptor for zona pellucida in humans

The effects of purified human sperm fertilization antigen-1 (FA-1), affinity-purified monoclonal Fab' antibody to FA-1, and monoclonal Fab' antibody to phosphotyrosine residues on human sperm-zona interaction were investigated. The purified FA-1 antigen completely blocked sperm binding to zona pellucida (P < 0.0001). Also, the monoclonal Fab' antibodies to FA-1 antigen and phosphotyrosine residues significantly (P < 0.05) reduced sperm-zona pellucidae and the antibodies were preincubated with sperm before insemination and not vice versa. These results suggest that the tyrosine phosphorylation especially of FA-1 antigen has an important role in zona pellucida receptor recognition and binding. These findings also suggest that FA-1 antigen may be the sperm receptor involved in zona pellucida binding in humans.

Characterization of human sperm antigens reacting with antisperm antibodies from autologous sera and seminal plasma in a fertile population

Immunoblotting techniques were used to characterize the reactivity of human sperm antigens with antisperm antibodies from a population of fertile individuals. In particular, sperm antigens of each subject were tested with the same subject's antisperm antibodies present in blood serum and seminal plasma in an attempt to construct a preliminary map of the antigen domains of the normal spermatozoon. Fifty-five fertile males, comprising 22 subjects with a pregnant partner and 33 subjects attending assisted reproductive technology sessions for proven partner's infertility and with normal semen quality entered the study. A high proportion of sera (82%) and seminal plasma (62%) showed antisperm antibodies reacting with one or more sperm antigens. Specific immunoreactivity was often demonstrated to 45-kDa, 50-kDa, 55-kDa, 69-kDa, 72-kDa and 85-kDa proteins in serum and to 59-kDa and 72-kDa proteins in seminal plasma. These proteins are the most frequently involved sperm antigens in the immune responses in fertile subjects. Further studies in an infertile population are necessary to distinguish between these antigens of minor relevance in sperm function from others significantly involved in immunological infertility.

Molecular identities of human sperm proteins that bind human zona pellucida: nature of sperm-zona interaction, tyrosine kinase activity, and involvement of FA-1

The present study was conducted to investigate the molecular identities, nature of interaction, and tyrosine phosphorylation activity of the sperm-zona pellucida binding proteins in humans. Sperm proteins belonging to four major molecular regions, namely 95, 63, 51, and 14-18 kDa, reacted with zona pellucida proteins in the Western blot and immunoprecipitation procedures. In these procedures, zona pellucida protein that reacted strongest with the sperm proteins belonged to the molecular region of 55 kDa (ZP3), besides weakly reacting proteins in the 110-kDa (ZP1/ZP2) and 14-18-kDa molecular regions. The major forces involved in the sperm-zona protein interactions were of hydrophobic and ionic in nature. Three (95, 51, and 14-18 kDa) of the four molecular regions of sperm proteins that bound to the zona pellucida proteins also seem to involve o-phospho-L-tyrosine residues in their interaction, and these proteins demonstrated the presence of phosphotyrosine residues, and the 51-kDa protein also showed autophosphorylating activity in the in vitro kinase assay. The sperm binding zona protein of 55 kDa also demonstrated autophosphorylating activity. Using specific monoclonal antibody to the well characterized sperm-specific glycoprotein, designated FA-1, and the competitive inhibition in the immunoprecipitation procedure, it was found that the 51 kDa protein is indeed FA-1 antigen. Besides elucidating the molecular nature of the sperm-zona interaction, these antigens will find application in the development of a multivalent contraceptive vaccine, and may also help in specific diagnosis and treatment of infertility mediated through defective gamete (sperm or oocyte) function.

Antibodies to sperm-specific human FA-1 inhibit in vitro fertilization in rhesus monkeys: development of a simian model for testing of anti-FA-1 contraceptive vaccine

The feasibility of using the rhesus monkey as a non-human primate model for testing the efficacy of a contraceptive vaccine based on FA-1 antigen was evaluated. Affinity-purified anti-FA-1 polyclonal antibodies (Fab' fragments) and anti-FA-1 monoclonal antibody were used as probes in these studies. Anti-FA-1 antibodies (polyclonal Fab' as well as monoclonal IgG) predominantly reacted with the postacrosomal, mid-piece and tail regions of rhesus monkey sperm, as with human sperm, by an indirect immunofluorescence technique (IFT). These antibodies also specifically recognized a single protein band of 51 +/- 2 kDa, corresponding to the dimeric form of FA-1 antigen, on a Western blot of lithium diiodosalicylate (LIS)-solubilized monkey sperm. Anti-FA-1 antibodies, when present in the insemination mixture, inhibited the in vitro fertilization (IVF) of monkey oocytes. These results indicate that FA-1 antigen in rhesus monkey sperm is similar in subcellular localization, molecular identity and function to that in human sperm, and that the rhesus monkey represents a permissible non-human primate model in which the efficacy of a contraceptive vaccine based on FA-1 antigen can be tested.

Antisperm antibodies: origin, regulation, and sperm reactivity in human infertility

OBJECTIVE

To follow-up and expand discussion on the action mechanisms of antisperm antibodies in human infertility, the etiology and control of antisperm antibody induction, sperm antigens involved in immunoinfertility, and strategies for therapy.

DESIGN

A review of the recent literature with an emphasis on female immunoinfertility.

RESULTS

The role of antisperm antibodies in clinical infertility continues to be defined. Through assisted reproductive technologies, antisperm antibodies were shown to exert detrimental effects on different prefertilization and possibly postfertilization events. The female reproductive tract is part of the common mucosal immune system and is able to mount effective immune responses against infectious agents, foreign antigens, and, occasionally, sperm cells. Sperm membranes and constituents contain numerous antigenic components foreign to the human body, and yet antisperm antibodies become problematic in few women exposed to semen. Semen and sperm cells contain immunosuppressive factors capable of inhibiting different immune cells. Fertile women apparently produce antisperm antibodies but also possess neutralizing serum anti-idiotypic antibodies that are lacking in virgin and immunoinfertile women.

CONCLUSIONS

Antisperm antibodies can affect adversely human fertility but normally may be controlled by anti-idiotypic antibodies, which along with immunosuppressor factors in semen prevent their induction to a significant degree. This balance between detrimental and "beneficial" immune response to sperm may be shifted toward an antisperm antibody response by stimulatory factors such as infection. Therapies may be devised to stimulate the anti-idiotypic antibody system, to induce immune tolerance to sperm antigens, and to use antigens to adsorb antisperm antibodies from spermatozoa.

Significance of antibodies against human sperm FA-1 antigen in immunoinfertility

A fertilization antigen (FA-1) has been identified on human sperm cells that is involved in human fertilization. To better explain the participation of FA-1 in human infertility, the relationship of anti-FA-1 antibodies with the presence of general antisperm antibodies and with sperm function was examined in the sera of 30 men and women. None of the sera from fertile men and women (n = 10) reacted with FA-1. In contrast, 55% of the immunoinfertile sera (n = 20) that were positive for antisperm antibodies detected by OPTI-BEAD (immune-labeled microsphere) tested positive with FA-1 (p < .05). In these sera, penetration of hamster oocytes was reduced and was inversely related to monospecific anti-FA-1 absorbance values determined by an ELISA and with heterospecific general antisperm antibody binding to sperm in the OPTI-BEAD test (p < .05). Anti-FA-1 activity approached significance with antisperm antibody binding to the sperm head (p = .052). It is concluded that immunoinfertile sera have antibodies reacting with the FA-1 sperm antigen and their presence is significantly related to results of other functional tests, such as the SPA and the OPTI-BEAD test. The association of anti-FA-1 antibodies with antibody binding site (sperm head) may be relevant to the diagnosis and treatment of immunoinfertility.

Antiidiotypic antibodies to sperm in sera of fertile women that neutralize antisperm antibodies

The presence of antiidiotypic antibodies (ab-2) to sperm was investigated in the sera of fertile, infertile, and virgin women using sperm-specific anti-FA-1 monoclonal antibody Fab'.ab-2 were detected in 71% (17/24) of sera from fertile women and in none (0/12) of the sera from virgin females by the enzyme-linked immunosorbent assay, Western blot procedure, and immunoprecipitation procedure. Sera from infertile women that had antisperm antibodies showed a minimal presence of ab-2, with only three sera (13%, 3/23) demonstrating the presence of low levels of ab-2. The ab-2 present in fertile women were capable of neutralizing the fertilization-inhibitory activity of anti-FA-1 antibody in a concentration-dependent manner in a human sperm penetration assay (SPA) of zona-free hamster oocytes. ab-2 were also capable of inhibiting the binding of antisperm antibodies to the sperm surface as determined by the immunobead binding technique. This is the first report demonstrating the presence of ab-2 in the sera of fertile women that are capable of neutralizing antisperm antibodies present in sera of infertile women. These findings suggest that the inability to detect antisperm antibody activity in the sera of fertile women may be due to higher levels of ab-2 present in these sera than levels found in sera of infertile women, although both groups may be producing antisperm antibody response after sexual exposure to sperm.

Is spermatozoan acrosin a predictor of fertilization and embryo quality in the human?

OBJECTIVE

To investigate whether acrosin is a more reliable criterion than conventional parameters for assessing semen samples.

DESIGN

Total acrosin was estimated biochemically in semen samples obtained for routine screening for infertility and for IVF-ET procedures.

SETTING

Assisted Conception Unit, St. James's University Hospital, Leeds, United Kingdom.

PATIENTS

Four hundred sixty-three couples being investigated for causes of infertility, and 132 couples undergoing IVF-ET for any indication except antisperm antibodies between 1990 and 1991 were included in the study.

INTERVENTIONS

Semen samples were collected as part of routine investigation. Samples from men with consistently high viscosity were collected in alpha-chymotrypsin.

MAIN OUTCOME MEASURES

Total spermatozoan acrosin in motile spermatozoa and motile spermatozoan density in couples being assessed for IVF-ET and fertilization and embryo quality in those receiving treatment are considered.

RESULTS

Total acrosin levels were less variable (within subject) than either total or motile spermatozoan concentration at ejaculation. Although severely oligozoospermic ejaculates had the lowest levels of total acrosin, overall, there was no significant correlation of spermatozoan concentration between total acrosin levels and percentage fertilization.

CONCLUSIONS

Total spermatozoan acrosin activity correlates positively with fertilization rates but not with spermatozoan count. Motile spermatozoan density for insemination may be adjusted to achieve > 7.5 microIU acrosin per oocyte, without compromising fertilization or further embryo development to blastocysts in vitro.

Immunoglobulin (Ig) G, IgA, and IgA subclass antibodies against fertilization antigen-1 in cervical secretions and sera of women of infertile couples

OBJECTIVES

To assess the occurrence of immunoglobulin (Ig) G, IgA, and IgA subclass antibodies against human sperm fertilization antigen-1 (FA-1) in cervical mucus (CM) and serum of women of infertile couples.

DESIGN

Enzyme-linked immunosorbent assay methodology was used to detect anti-FA-1 antibodies. Antisperm antibodies were detected by agglutinating, immobilizing, and indirect immunobead (IB) methods. Control samples for the ELISA were from 10 women negative in the antisperm antibody assays.

PARTICIPANTS

Samples were from women of 32 infertile couples undergoing antisperm antibody analysis.

RESULTS

One of 10 control CM samples was slightly positive for IgG anti-FA-1 and none for IgA. Of the 22 CM samples from antisperm antibody-positive women, 9 were positive for IgG antibodies, 9 for IgA, 7 for IgA1, and 6 for IgA2. Cervical mucus samples from eight women were positive for both IgA and IgG antibodies. Assay of 19 serum samples, including 8 controls, by ELISA, indicated 9 of 11 from antisperm antibody-positive women and none from controls were positive for IgA and IgG (7 of 9 identical women). In addition, of the nine IgA-positive sera, seven were of the A1 subclass and five were of the A2 subclass. Positive IB assays occurred more frequently in CM and serum samples positive for anti-FA-1 antibodies than in negative samples.

CONCLUSION

The results suggest that cervical secretions and sera of antisperm antibody-positive women contain IgA and IgG antibodies against sperm antigen FA-1 that may be involved in antifertility effects.

The fertilization antigen-1 does not have proteolytic/acrosin activity, but its monoclonal antibody inhibits sperm capacitation and acrosome reaction

OBJECTIVE

To determine if human sperm surface fertilization antigen exhibits proteolytic or acrosin activity and to investigate the mechanism(s) whereby monoclonal antibody (mAb) to fertilization antigen inhibits human sperm penetration of zona-free hamster ova.

DESIGN

Proteolytic and acrosin activities of human fertilization antigen were determined. Acrosomal status, acrosin activity, and motion characteristics were evaluated after incubation of human sperm with immunoaffinity-purified mAb to fertilization antigen.

SETTING

Academic research environment.

PARTICIPANTS

Fertile donors used as controls for infertile patients for fertility evaluation.

INTERVENTIONS

Human spermatozoa were treated with mAb to fertilization antigen and induced to undergo acrosome reaction using calcium ionophore A23187.

MAIN OUTCOME MEASURES

Proteolytic and acrosin activities of fertilization antigen. Sperm penetration assay, acrosomal status, and motion parameters.

RESULTS

Fertilization antigen does not exhibit proteolytic or acrosin activity; however, its mAb completely blocks human sperm penetration of zona-free hamster ova. The mAb to fertilization antigen inhibits ionophore-induced acrosome reaction and blocks development of the hyperactivated state of human sperm cells.

CONCLUSIONS

Monoclonal antibody to fertilization antigen blocks fertilization by inhibiting capacitation and acrosome reaction.